Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE8B | O95263 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL80021 | 1.00 | PDE8B (0.49) | PDE8BKDM1AATMHSD17B10HPGD | |
| SCHEMBL283705 | 1.00 | PDE8B (0.49) | PDE8BKDM1AATMHSD17B10HPGD | |
| SCHEMBL20214777 | 0.98 | PDE8B (0.48) | PDE8BKDM1AATMHSD17B10HPGD | |
| Hydrochloric Acid SCHEMBL3564519 | 0.98 | PDE8B (0.48) | PDE8BKDM1AATMHSD17B10HPGD | |
| SCHEMBL20186804 | 0.98 | PDE8B (0.48) | PDE8BKDM1AATMHSD17B10HPGD | |
| SCHEMBL337349 | 0.95 | HSD17B10 (0.48) | PDE8BATMHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL337037 | 0.95 | HSD17B10 (0.48) | PDE8BATMHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL205359 | 0.95 | HSD17B10 (0.48) | PDE8BATMHSD17B10SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1027414 | 0.94 | HSD17B10 (0.47) | PDE8BATMHSD17B10SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1026857 | 0.94 | HSD17B10 (0.47) | PDE8BATMHSD17B10SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617779-B2 | Self degradation-type CDK9 inhibitor prodrug and liposome encapsulating same | Sumitomo Pharma Co., Ltd. (JP) | 2026-05-05 | — | — | US | disclosed |
| EP-3710458-B1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4580620-A2 | PYRAZOLE AND IMIDAZOLE DERIVATIVES AS DUAL OREXIN AND KAPPA-OPIOID RECEPTORS MODULATORS, COMPOSITION, METHODS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | Hager Biosciences, LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| US-12312370-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20250034200-A1 | Prodrugs of Neurosteroid Analogs and Uses Thereof | UNIV EMORY (US) | 2025-01-30 | — | — | US | disclosed |
| US-20240368138-A1 | SELF DEGRADATION-TYPE CDK9 INHIBITOR PRODRUG AND LIPOSOME ENCAPSULATING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2024-11-07 | — | — | US | disclosed |
| CN-115894447-B | METTL3 inhibitors and uses thereof | 成都先导药物开发股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240262830-A1 | IRE1A MODULATORS AND USES THEREOF | NIMBUS IASO, INC. | 2024-08-08 | — | — | US | disclosed |
| EP-4393918-A1 | SELF DEGRADATION-TYPE CDK9 INHIBITOR PRODRUG AND LIPOSOME ENCAPSULATING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2024-07-03 | — | — | EP | disclosed |
| WO-2024138157-A1 | NOVEL IMIDAZOQUINOLINES WITH IMMUNOSTIMULATORY EFFECTS | SYNOVO GMBH (DE) | 2024-06-27 | — | — | WO | disclosed |
| US-20060183745-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-08-17 | — | — | US | disclosed |
| WO-2006028904-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-03-16 | — | — | WO | disclosed |
| EP-1289955-B1 | PIPERIDINES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2005-04-13 | — | — | EP | disclosed |
| US-20040143115-A1 | N-aroyl cyclic amines | SMITHKLINE BEECHAM LIMITED (GB) | 2004-07-22 | — | — | US | disclosed |
| EP-1385845-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM PLC (GB) | 2004-02-04 | — | — | EP | disclosed |
| US-6677354-B2 | TREATING SLEEP, BRAIN, SEXUAL, CARDIOVASCULAR, NERVOUS SYSTEM, PSYCHOLOGICAL, GLANDULAR, AND GASTROINTESTINAL DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-01-13 | — | — | US | disclosed |
| US-20030186964-A1 | Piperdines for use as orexin receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-10-02 | — | — | US | disclosed |
| EP-1289955-A1 | PIPERIDINES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2003-03-12 | — | — | EP | disclosed |
| WO-2002090355-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-11-14 | — | — | WO | disclosed |
| WO-2001096302-A1 | PIPERIDINES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617779-B2 | Self degradation-type CDK9 inhibitor prodrug and liposome encapsulating same | CDK9, CDK6, CDK19 | PDE8B 1651/4885KDM1A 36/4885ATM 1753/4885 |
| US-12312370-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | PDE8B 3177/4885KDM1A 410/4885ATM 3544/4885 |
| US-20240262830-A1 | IRE1A MODULATORS AND USES THEREOF | XBP1, HSPA5, ERN2 | PDE8B 2008/4885KDM1A 3551/4885ATM 3391/4885 |
| US-20060183745-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | PDE8B 2614/4885KDM1A 3574/4885ATM 2722/4885 |
| US-20250034200-A1 | Prodrugs of Neurosteroid Analogs and Uses Thereof | CYP11B2, CYP11B1, CYP21A2 | PDE8B 1258/4885KDM1A 3301/4885ATM 2713/4885 |
| US-20040143115-A1 | N-aroyl cyclic amines | HCRTR1, HCRTR2, CNR1 | PDE8B 3137/4885KDM1A 522/4885ATM 4061/4885 |
| US-20240368138-A1 | SELF DEGRADATION-TYPE CDK9 INHIBITOR PRODRUG AND LIPOSOME ENCAPSULATING SAME | CDK9, CDK19, CDK6 | PDE8B 1686/4885KDM1A 40/4885ATM 1500/4885 |
| US-20030186964-A1 | Piperdines for use as orexin receptor antagonists | HCRTR2, HCRTR1, NPSR1 | PDE8B 4562/4885KDM1A 1254/4885ATM 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.